From Nasdaq:

The U.S. FDA has granted Fast Track Designation to Verastem Oncology’s avutometinib, in combination with Amgen’s LUMAKRASTM, for the treatment of KRAS G12C-mutant metastatic non-small cell lung cancer. Fast Track is meant to expedite the review of new drugs for serious conditions and unmet medical needs.

Verastem (VSTM) closed Thursday’s regular trading at $10.39, down $0.72 or 6.48%. However, in after-hours trading, the stock gained $0.84 or 8.08%.

For more health news, visit rttnews.com.



Read more: Verastem : Avutometinib Combination Receives Fast Track Designation For KRAS G12C-Mutant NSCLC